STRATTERA (nda021411)- (EQ 5MG BASE,EQ 10MG BASE,EQ 18MG BASE,EQ 25MG BASE,EQ 40MG BASE,EQ 60MG BASE,EQ 80MG BASE,EQ 100MG BASE)

Generic Name	ATOMOXETINE HYDROCHLORIDE	Innovator	LILLY
Dosage	EQ 5MG BASE,EQ 10MG BASE,EQ 18MG BASE,EQ 25MG BASE,EQ 40MG BASE,EQ 60MG BASE,EQ 80MG BASE,EQ 100MG BASE
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2017-May-26	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	STRATTERA ® is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
8	2	7

Other Developers

Total Other Developers	12

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
EQ 5MG BASE	**	**	-	-	-
EQ 10MG BASE	**	**	-	-	6
EQ 18MG BASE	**	**	-	-	6
EQ 25MG BASE	**	**	-	-	6
EQ 40MG BASE	**	**	-	-	6
EQ 60MG BASE	**	**	-	-	6
EQ 80MG BASE	**	**	-	-	6
EQ 100MG BASE	**	**	-	-	6

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	6

Manufacturing Details of STRATTERA